NCT05930730View on ClinicalTrials.gov

Immunogenicity and Safety of Comvigen (Bivalent) Vaccine

PHASE2RecruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

October 9, 2023

Primary Completion Date

February 29, 2024

Study Completion Date

February 29, 2024

Conditions
Safety of a Single Dose of COMVIGEN VaccineReactogenicity of a Single Dose of COMVIGEN VaccineImmunogenicity of a Single Dose of COMVIGEN VaccineSafety of a Single Dose of BIVALENT Pfizer/BNT VaccineReactogenicity of a Single Dose of BIVALENT Pfizer/BNT VaccineImmunogenicity of a Single Dose of BIVALENT Pfizer/BNT Vaccine
Interventions
BIOLOGICAL

Comvigen (Bivalent, ChulaCov19 BNA159.2)

single dose of COMVIGEN at 50 ug, as a booster dose, given at 3 months and above after receipt of a previous booster dose of any approved mRNA COVID-19 vaccine

BIOLOGICAL

BIVALENT Pfizer/BNT vaccine

single dose of BIVALENT of Pfizer/BNT Bivalent vaccine at 30 ug, as a booster dose, given at 3 months and above after receipt of a previous booster dose of any approved mRNA COVID-19 vaccine

Trial Locations (2)

10330

RECRUITING

Department of Pediatric, Faculty of Medicine, Chulalongkorn University, Bangkok

RECRUITING

HIV-NAT, Thai Red Cross - AIDS Research Centre, Bangkok

All Listed Sponsors
collaborator

Chula Clinical Research Center (Chula CRC), Faculty of Medicine Chulalongkorn University, Bangkok, Thailand

UNKNOWN

collaborator

HIV-NAT, Thai Red Cross - AIDS Research Centre

UNKNOWN

lead

Chulalongkorn University

OTHER